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Breast carcinoma is one of the most common malignancies in
women worldwide. Human breast tissue is a target for oestrogens,
and these sex steroids have an important role to play in the devel-
opment of hormone-dependent breast carcinomas (Thomas, 1984;
Vihko and Apter, 1989). The biological effects of oestrogens are
mediated through an initial interaction with the oestrogen receptor
(ER), a member of the superfamily of nuclear receptors. Recently,
a second ER, ERβ , has been identified in humans (Kuiper et al,
1996; Mosselman et al, 1996), and the previously known human
ER has been renamed ERα (Mosselman et al, 1996; Enmark et al,
1997). ERs are known to function as dimers, and to activate tran-
scription in a ligand-dependent manner by binding to oestrogen-
responsive elements (EREs) located in the promoter region of
various target genes (Tsai and O’Malley, 1994). Therefore, it is
very important to examine the expression of oestrogen-responsive
genes to obtain a better understanding of oestrogenic actions and
their regulation in hormone-dependent breast carcinomas. 
Recently, EBAG9 (oestrogen receptor-binding fragment-
associated gene 9) has been identified as an oestrogen-responsive
gene from a cDNA library of MCF-7 human breast cancer cells
(Watanabe et al, 1998). EBAG9 is identical to the receptor-binding
cancer antigen expressed in SiSo cells (RCAS1) (Nakashima et al,
1999). RCAS1 is expressed in uterine, ovarian and lung cancers
and has been suggested to be associated with a poor prognosis in
these patients (Sonoda et al, 1996; Kaku et al, 1999; Iwasaki et al,
2000). EBAG9/RCAS1 is a membrane molecule that acts as a
ligand for a putative receptor present in cells (Nakashima et al,
1999). In vitro studies have also demonstrated that EBAG9/
RCAS1 inhibits growth of activated CD3+ T lymphocytes,
suggesting a possible involvement in the immune escape of
neoplastic cells (Nakashima et al, 1999). Endocrine–immune
interactions are considered to play an important role in the devel-
opment and/or progression of various hormone-dependent human
neoplasms, but the details of these interactions remain unclear.
EBAG9 may play an important role in the development of
oestrogen-dependent breast carcinomas, possibly through modula-
tion of intratumoural immune environment. However, the expres-
sion of EBAG9 has not been examined in breast carcinoma tissues,
and thus the biological significance remains unknown. Therefore,
in this study, we examined the expression of EBAG9 in human
breast carcinomas using immunohistochemistry and reverse
transcription-polymerase chain reaction (RT-PCR). In addition, we
statistically correlated the immunoreactivity of EBAG9 with
various clinicopathological parameters in 91 cases of human
breast carcinoma in order to study the possible roles of EBAG9 in
hormone-dependent breast cancer. 
MATERIALS AND METHODS 
Patients and tissues 
91 specimens of invasive ductal carcinoma of the breast were
obtained from female patients who underwent mastectomy from
1984 to 1989 in the Department of Surgery, Tohoku University
Hospital, Sendai, Japan. Metastatic lesions in the resected lymph
nodes were also examined in this study. The mean age of patients
from whom specimens were obtained was 53.7 years (range
27–82). All patients examined in this study received neither irradi-
ation nor chemotherapy prior to surgery. The clinical data,
including patient age, menopausal status, stage according to UICC
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were retrieved from patient charts. The mean follow-up time was
104 months (range 15–154 months). Disease-free survival data
were available for all patients. The histological grade of each spec-
imen was evaluated by 3 of the authors (TS, TM, and HS), based
on the modified method of Bloom and Richardson (1957),
according to Elston and Ellis (1991). The intratumoural mononu-
clear infiltration grade of carcinomas was assessed as 0 (no areas),
1 (scattered small foci), 2 (scattered large foci), and 3 (numerous
large or broad areas with pertinent changes), based on the method
of Hamlin (1968) by these 3 authors. 
All specimens were fixed with 10% formalin and embedded in
paraffin-wax in the Department of Pathology, Tohoku University
Hospital, Sendai, Japan. 
Antibodies 
EBAG9 antibody was a rabbit polyclonal antibody against a GST-
EBAG9 fusion protein (Tsuchiya et al, 2001). The Polyclonal anti-
body for ERβ was raised in rabbit against synthesized peptides of
the C-terminal region of ERβ (CSPAEDSKSKEGSQNPQSQ)
(Ogawa et al, 1998b). These antibodies were purified on affinity
columns bound with the synthetic peptides. The characterization
of these antibodies was confirmed by Western blotting (Ogawa et al,
1998b; Tsuchiya et al, 2001), and utilization of the ERβ antibody for
immunohistochemistry has been previously reported (Takeyama et al,
2001). Monoclonal antibodies for ERα (ER1D5), PR (MAB429),
and Ki-67 (MIB1) were purchased from Immunotech (Marseille,
France), Chemicon (Temecula, CA, USA), and Immunotech 
(Marseille, France), respectively. Rabbit polyclonal antibodies for
CD3 (A0452), which recognizes T lymphocytes, and HER-2/neu
(A0485) were obtained from DAKO (Carpinteria, CA, USA). 
Western blot analysis 
For characterization of EBAG9 antibody, Western blot analysis
was performed using recombinant EBAG9 protein. Full lengths of
mouse and human EBAG9 ORF cDNA were ligated into eukary-
otic expression vector pcDNA3 (Invitrogen), and then mouse and
human EBAG9 proteins were produced using TNT 17 Quick
Coupled Transcription/Translation System (Promega, Madison,
WI, USA). Western blot analysis was performed as described
(Ogawa et al, 1998b). Briefly, 10 µ g of each sample was fraction-
ated on SDS-12.5% polyacrylamide gels, and electrophoretically
transferred onto polyvinylidene difluoride (PVDF) membranes
(Immobilon, Millipore Corp, Bedford, MA, USA). The membranes
were blocked at room temperature for 1 h in phosphate-buffered
saline (PBS) with 3% skim milk, then incubated at room tempera-
ture for 1 h with 5 ml each of 1:2000 diluted purified anti EBAG9
antibody, which was incubated with 0.1, 1, 10 and 100 µ g of GST-
EBAG9 fusion protein at 4˚C for 12 h. Each membrane was
washed in PBS with 0.1% Tween 20 and incubated with 1:5000
diluted horseradish peroxidase-conjugated donkey anti-rabbit IgG
(Amersham Pharmacia Biotech) at room temperature for 1 h.
Bands were visualized with the chemiluminescence-based ECL™
or ECL™ plus detection system (Amersham Pharmacia Biotech).
The membranes were exposed to X-ray film or placed on the
STORM™ system (Molecular Dynamics, Sunnyvale, CA, USA).
To detect the distribution of EBAG9 at the protein level, tissue of
8-week ICR mice purchased from SLC (Shizuoka, Japan) were
collected and homogenized in lysis buffer (5 mM phosphate
buffer, pH 7.4, with 0.1% Triton X-100), then 10 µ g of each
sample was used for Western blot analysis. 
Immunohistochemistry 
Immunohistochemical analysis was performed by employing the
streptavidin–biotin amplification method using a Histofine Kit
(Nichirei, Tokyo, Japan) for EBAG9, ERα , PR, Ki-67, HER-
2/neu, and CD3, or EnVision+ (DAKO, Carpinteria, CA, USA) for
ERβ in this study. For antigen retrieval, the slides were heated in
an autoclave at 120˚C for 5 min in citric acid buffer (2 mM citric
acid and 9 mM trisodium citrate dehydrate, pH 6.0) for the
immunostaining of EBAG9, ERα , ERβ , PR, Ki-67, and HER-
2/neu or incubated with 0.05% protease (Type XXVII; Sigma,
St Louis, MO, USA) in 50 mM Tris-HCl buffer, pH 7.6 for 10 min
for CD3, following deparaffinization. The dilutions of primary
antibodies used in this study were as follows: EBAG9; 1/200,
ERα ; 1/2, ERβ ; 1/100, PR; 1/30; Ki-67; 1/50, HER-2/neu; 1/200,
and CD3; 1/500. The antigen–antibody complex was visualized
with 3.3′ -diaminobenzidine (DAB) solution (1 mM DAB, 50 mM
Tris-HCl buffer (pH 7.6), and 0.006% H2O2), and counterstained
with methyl green. For negative controls, normal rabbit or mouse
IgG was used instead of the primary antibodies. For EBAG9 and
ERβ , immunohistochemical preabsorption tests were also perform-
ed. No specific immunoreactivity was detected in these sections. 
RT-PCR 
RT-PCR analysis was performed on 7 specimens of invasive ductal
carcinoma. Total RNA was extracted by homogenizing tissue
specimens in guanidinium thiocyanate followed by ultracentrifu-
gation in cesium chloride, and quantified spectrophotometrically at
260 nm. A cDNA synthesis kit (SUPERSCRIPT Preamplification
system, Gibco-BRL, Grand Island, NY, USA) was employed in the
synthesis of first-strand cDNA. cDNAs were synthesized from 5 µ g
of total RNA using random hexamer primer. Reverse transcription
was carried out for 60 min at 42˚C with SUPERSCRIPT II reverse
transcriptase. After an initial 1-min denaturation step at 95˚C, 40
cycles of PCR were carried out on a LightCycler (Roche Diagnostics
GmbH, Mannheim, Germany) under the following conditions: 1-min
denaturation at 95˚C, 15-s annealing at 58˚C for EBAG9, 62˚C for
ERα , or 60˚C for ERβ and β -actin, and 15-s extension at 72˚C. The
primer sequences used in this study are as follows: EBAG9
(FWD 5′ and REV 5′ -CTTCTTCATTAGCCGTTGTG), ERα (FWD 
5′ -AAGA GCTGCCAGGCCTGCC and REV 5′ -TTGGCAGCTCT-
CATGTCTCC) (Pujol et al, 1998), ERβ (FWD 5′ -GCATGGAA-
CATCTGCTCAAC and REV 5′ -ACGCTTCAGCTTGTGAC-
CTC) (Ogawa et al, 1998a), and β -actin (FWD 5′ -CCAACCGC-
GAGAAGATGAC and REV 5′ -GGAAGGAAGGCTGGAA-
GAGT). Oligonucleotide primers for EBAG9 and β -actin were
designed using perviously published cDNA sequences for human
EBAG9 (Watanabe et al, 1998) and β -actin (Ponte et al, 1984),
respectively. Following PCR, the products were resolved on a 2%
agarose eithidium bromide gel, and images were captured with
Polaroid film under UV transillumination. In initial experiments,
following amplification, PCR products were purified and
subjected to direct sequencing (ABI PRISM BigDye Terminator
Cycle Sequencing Ready Reaction Kit, Perkin Elmer Applied
Biosystems, Foster City, CA, USA; and ABI Prism 310 Genetic
Analyzer) to verify amplification of the correct sequences. As a
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(Watanabe et al, 1998) and ERα (Vladusic et al, 2000), and T-47D
breast carcinoma cells were used for ERβ (Vladusic et al, 2000).
Negative control experiments lacked the cDNA substrate to check
for the possibility of exogenous contaminant DNA. No amplified
products were observed under these conditions. 
Scoring of immunoreactivity 
For statistical analyses of EBAG9 and HER-2/neu immuno-
reactivity, carcinomas were classified independently by 3 of the
authors (TS, TM and HS) into 2 groups: +, positive carcinoma
cells; and –, no immunoreactivity. Cases with disconcordant
results among the observers were re-evaluated. Scoring of ERα ,
ERβ , PR and Ki-67 in carcinoma cells was performed on high-
power fields ( × 400) using a standard light microscope. In each
case, more than 500 carcinoma cells were counted independently
by these same 3 authors, and the percentage of immunoreactivity,
i.e. labelling index (LI), was determined. In the present study,
inter-observer differences were less than 5%, and the mean of the
3 values was obtained. To determine the infiltration of T lympho-
cytes, 3 of the authors (TS, TM and HS) independently counted
the number of CD3+ cells on high-power fields ( × 400) using a
standard light microscope. For each specimen, 6 fields were
selected at random in the invasive margin of the cancer. Inter-
observer differences were less than 5%, and the mean of the 3
values was obtained. 
Statistical analysis 
Values for patient age, tumour size, and LIs for ERα , ERβ , PR,
Ki-67 and CD3+ cells were presented as mean ± 95% confidence
interval (95% CI), and the association between immunoreactivity
for EBAG9 and these parameters were evaluated using a
Bonferroni test. Statistical differences between immunoreac-
tivity for EBAG9 and menopausal status, stage, lymph node
status, histological grade, mononuclear infiltration grade and
HER-2/neu were evaluated in a cross-table using a χ 2 test.
Disease-free and overall survival analyses were calculated
according to the Kaplan–Meier test. P values less than 0.05 were
considered significant. The statistical significance of the differences
in the survival analyses was calculated using the log-rank test.
RESULTS 
Characterization of anti-EBAG9 antibody by Western
blot analysis 
The specificity of the anti-EBAG9 antibody was shown in Figure 1.
Western blot analysis of human and mouse EBAG9 proteins
revealed that the polyclonal antibody reacted with both in vitro
translated human and mouse EBAG9 at 32 kDa. The band inten-
sity of both human and mouse EBAG9 was abolished by pre-
absorption according to the amount of added recombinant EBAG9
fusion protein in primary antibody before reaction with the
membrane, suggesting that the reactivity of the antibody is specific
to EBAG9 of both mouse and human. 
Immunohistochemistry 
EBAG9 immunoreactivity was detected on the entire surface, and
in the cytoplasm of invasive ductal carcinoma cells (Figure 2A).
The number of cases immuno-positive for EBAG9 was 82 out of
91 cases (90.1%). In morphologically normal glands, immunore-
activity for EBAG9 was weakly detected on the luminal surface of
epithelial cells (Figure 2B). 
Immunoreactivity for ERα (Figure 2C), ERβ , and PR was
detected in the nuclei of carcinoma cells, and that for Ki-67 was
detected in the nuclei of carcinoma cells as well as some stromal
cells. CD3+ cells were distributed mainly in the invasive margin as
well as in the stroma (Figure 3A, B), and the distribution pattern
was similar to that of leukocytes by conventional H&E stain. In
this study, HER-2/neu immunoreactivity was detected in the
membranes of carcinoma cells in 39 out of 91 cases (42.9%). 
RT-PCR 
As shown in Figure 4, mRNA expression for EBAG9, ERα and
ERβ was detected as a specific single band (213 bp for EBAG9,
168 bp for ERα , and 228 bp for ERβ ) in 7 out of 7 cases (100%),
respectively. All the cases examined for RT-PCR analyses were
immunohistochemically positive for EBAG9, ERα and ERβ . 
Relationship between EBAG9 and clinicopathological
parameters 
The results of association between EBAG9 and clinicopatholog-
ical parameters are summarized in Table 1. As shown in Table 1, a
significant inverse association was detected between EBAG9
immunoreactivity and mononuclear infiltration grade of the carci-
noma tissue (P = 0.0020). There was, however, no significant rela-
tionship between EBAG9 immunoreactivity and patient age,
menopausal status, stage, tumour size, lymph node status or histo-
logical stage. 
Relationship between EBAG9 and steroid receptors 
Results of association between EBAG9 and immunohistochemical
parameters are summarized in Table 2. There was a significant posi-
tive association between EBAG9 immunoreactivity and ERα LI 
(P = 0.0081). There was a significant inverse association between
EBAG9 immunoreactivity and infiltration of CD3+ cells (P =
0.0025). Other significant associations were not detected in this
study. 
Relationship between primary and metastatic tumours 
In the present investigation, lymph node metastasis was detected
in 48 cases. As shown in Table 3, a significant association 
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Figure 1 Specificity of EBAG9 antibody by Western blot analysis. Lanes 3,
6, 9, 12 and 15 were loaded with a premix of TNT T7 Quick Coupled
Transcription/Translation System as control. Lanes 1, 4, 7, 10 and 13 were
loaded with in vitro translated mouse EBAG9 protein, and lanes 2, 5, 8, 11
and 14 were loaded with recombinant human EBAG9, as described in the
Materials and Methods. Lanes 1 to 3 were incubated with 5 ml of 1:2000
diluted purified anti-EBAG9 antibody. Lanes 4 to 6, lanes 7 to 9, lanes 10 to
12, and lanes 13 to 15 were incubated with 5 ml of 1:2000 diluted purified
anti-EBAG9 antibody, each of which was incubated before for 12 h at 4˚C
with 0.1 µ g, 1 µ g, 10 µ g, and 100 µ g of GST-EBAG9 fusion protein,
respectively. kDa; kilodalton (P = 0.031) was detected between immunoreactivity for EBAG9
in the primary lesion, and in the lymph node metastasis in these
cases. 
Relationship between EBAG9 and clinical outcome 
As shown in Table 4, no significant relationship was detected
between EBAG9 immunoreactivity and disease-free (P = 0.4882)
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Figure 3 Immunohistochemistry for CD3 in invasive ductal carcinoma.
(A) Numerous CD3-positive cells were detected in the invasive margin of the
breast carcinoma. In this case, immunoreactivity for EBAG9 was negative
and ERα LI was 0. (B) Scattered CD3-positive cells were detected (arrows)
in the invasive margin of the breast carcinoma. In this case, immunoreactivity
for EBAG9 was positive, and ERα LI was 78 (the same case and same field as
Figure 2A, C). (C) Carcinoma. Original magnification × 140 and bar = 50 µ m,
respectively 
C
B
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Figure 2 Immunohistochemistry for EBAG9 in invasive ductal carcinoma.
(A) EBAG9 immunoreactivity was detected on the entire surface and in the
cytoplasm of invasive ductal carcinoma cells. (B) In morphologically normal
mammary glands, immunoreactivity for EBAG9 was weakly detected on the
luminal surface of epithelial cells (arrows). (C) Immunoreactivity for ERα was
detected in the nuclei of carcinoma cells. The same field as (A). Original
magnification   140 and bar = 50 µ m, respectively 
C
A
C
Bor overall (P = 0.6602) survival in the 91 invasive ductal carci-
nomas examined in this study. 
DISCUSSION 
In this study, EBAG9 immunoreactivity was detected in carcinoma
cells in 82 out of 91 human breast carcinomas (90.1%). EBAG9
immunoreactivity was significantly associated with ERα LI
(P = 0.0081), and although association did not reach statistical
significance, a similar tendency was also detected between EBAG9
and ERβ (P = 0.074). ERβ has been demonstrated to activate gene
transcription by binding to EREs of target genes (Enmark et al,
1997; Paige et al, 1999), as well as ERα . EBAG9 was
isolated utilizing a genomic binding site cloning method 
from a cDNA library of MCF-7 human breast cancer cells
(Watanabe et al, 1998), which expresses ERα and low level of ERβ
(Vladusic et al, 2000). Transfection analyses have demonstrated
that the nucleotide sequence between –86 to –36 contains an ERE
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Table 1 Association between EBAG9 immunoreactivity and
clinicopathological parameters in human breast carcinomas 
EBAG9 immunoreactivity P value 
+ (n = 82) – (n = 9) 
Agea (years) 53.9 ± 1.4 51.6 ± 4.1 NS 
Menopausal status 
Premenopausal 42 (46.2%) 6 (6.6%) 
Postmenopausal 40 (44.0%) 3 (3.3%) NS 
Stage 
I 16 (17.6%) 3 (3.3%) 
II 49 (53.8%) 3 (3.3%) 
III 12 (13.2%) 2 (2.2%) 
IV 5 ( 5.5%) 1 (1.1%) NS 
Tumor size* (mm) 28.7 ± 1.5 27.6 ± 3.7  NS 
Lymph node status 
Positive 43 (47.3%) 5 (5.5%) 
Negative 39 (42.9%) 4 (4.4%) NS 
Histological grade 
Grade I 21 (23.1%) 0 (0%) 
Grade II 30 (33.0%) 4 (4.4%) 
Grade III 31 (34.1%) 5 (5.5%) NS 
Mononuclear infiltration grade 
Grades 0 and 1 20 (22.0%) 0 (0%) 
Grade 2 45 (49.5%) 2 (2.2%) 
Grade 3 17 (18.7%) 7 (7.7%) 0.0020 
aData are presented as mean ± 95% confidence interval (95% CI). All other
values represent the number of cases and their respective percentages. 
P values less than 0.05 were considered as significant.
EBAG9
(213 bp)
ERα
(168 bp)
ERβ
(228 bp)
T-47D
β -actin
(459 bp)
500
500
500
500
MCF-7N
Breast carcinoma
MW
(bp) P 7 123456 N
Figure 4 Reverse transcription polymerase chain reaction (RT-PCR)
analysis for EBAG9, ERα , and ERβ in 7 invasive ductal carcinomas. mRNA
expression for EBAG9, ERα , ERβ , and β -actin was detected as a specific
single band (213 bp for EBAG9, 168 bp for ERα , 228 bp for ERβ , and 459 bp
for β -actin) in 7 out of 7 cases (100%), respectively. P, positive controls
(MCF-7 cells for EBAG9 and ERα , and T-47D cells for ERβ ); N, negative
control (no cDNA substrate) 
Table 2 Association between EBAG9 immunoreactivity and
immunohistochemical parameters in human breast carcinomas 
EBAG9 immunoreactivity P value 
+ (n = 82) – (n = 9) 
ERα LIa 46.1 ± 3.9 13.3 ± 6.2 0.0081 
ERβ LIa 9.5 ± 1.2 2.6 ± 5.2 NS 
PR LIa 43.0 ± 4.1 37.0 ± 14.4 NS 
Ki-67 LIa 26.9 ± 1.7 25.3 ± 6.6 NS 
Infiltration of CD3+ cellsa 124.1 ± 6.5 189.5 ± 22.1 0.0025 
HER-2/neu
Positive 33 (36.3%) 6 (6.5%)
Negative 49 (53.8%) 3 (3.2%) NS 
aData are presented as mean ± 95% confidence interval (95% CI). All other
values represent the number of cases and their respective percentages. 
P values less than 0.05 were considered as significant.
Table 4 Disease-free and overall survival analyses in breast cancer
patients examined 
Variable Disease-free Overall 
survival survival 
P value P value 
Lymph node status (positive/negative) 0.0035*  < 0.0001* 
Tumor size (> 20 mm/ ≤ 20 mm) 0.0133* 0.0115* 
HER-2/neu (positive/negative) 0.0647 0.0370* 
Ki-67 LI (≥ 10/< 10) 0.2099 0.1982 
Histological grade (III/I, II) 0.2358  0.0376* 
ERα LI (≥ 10/< 10) 0.2500  0.3760 
EBAG9 immunoreactivity (+/–) 0.4882 0.6602 
Disease-free and overall survival analyses were calculated according to the
Kaplan–Meier test. P values less than 0.05(*) were considered significant.
Table 3 Association between EBAG9 immunoreactivity in the primary lesion
and in lymph node metastasis of human breast carcinomas 
EBAG9 EBAG9 immunoreactivity in 
immunoreactivity in primary lesion P value 
lymph node metastasis
+ (n = 43) – (n = 5) 
+ (n = 44) 41 (85.5%) 3 (6.3%) 
– (n = 4) 2 ( 4.2%) 2 (4.2%)  0.031 
Data represent the number of cases and their respective percentages. P
value less than 0.05 was considered as significant.in the 5′ -promoter region of the EBAG9 gene (Ikeda et al, 2000).
mRNA levels of EBAG9 in MCF-7 cells are significantly increased
within 6 hours of oestrogen treatment, an effect that is mediated by
the binding of ERα to the ERE in the promoter of the EBAG9 gene
(Ikeda et al, 2000). Results from our present study are consistent
with these previous reports, and suggest that EBAG9 is widely
distributed in carcinoma cells of human breast carcinoma tissues as
a result of oestrogenic actions through ERα and/or ERβ . 
It is well known that the expression of ERβ depends on the pres-
ence of ERα in the great majority of human breast cancers (Sasano
et al, 1999; Skliris et al, 2001). However, the biological signifi-
cance of ERβ remains undefined in the breast cancer. Previously,
Speirs et al (1999) reported that breast tumours coexpressing ERα
and ERβ tended to be node positive and higher grade using RT-
PCR, and Dotzlaw et al (1999) have shown that ERβ mRNA level
was lower in PR-positive breast cancer. However, immunohisto-
chemical studies have demonstrated that ERβ -positive breast
cancers were predominantly well-differentiated, node-negative
and PR-positive (Jarvinen et al, 2000; Skliris et al, 2001). In our
immunohistochemical study, ERβ LI was inversely correlated
with histological grade (P = 0.0030) or lymph node status (P =
0.0059), and positively correlated with PR LI (P = 0.0182). These
present data are in good agreement with the latter reports.
Considering that the former studies were conducted at the mRNA
level, these different observations may partly reflect the discrep-
ancy between mRNA and protein levels of ERβ . 
There was a strong correlation between ERα LI and PR LI
(P < 0.0001) in this study, but no association was detected between
EBAG9 immunoreactivity and PR LI (P = 0.65). Transcription of
the PR gene is enhanced and maintained by oestrogens, and a posi-
tive PR status has been regarded as one of the markers of func-
tional oestrogenic pathways (Horwitz and Mcguire, 1978;
Alexieva-Figusch et al, 1988). Therefore, these findings suggest a
variety of oestrogenic actions, and different mechanisms may be
involved in the regulation of expression of these 2 oestrogen-
responsive genes in breast carcinomas. 
EBAG9 immunoreactivity was detected on the entire surface and
in the cytoplasm of invasive ductal carcinoma cells, while it was
present only on the side of the luminal surface of normal glandular
epithelia in this study. Similar findings have also been reported
in some cancer-associated antigens, including carcinoembrionic
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) (Hamada 
et al, 1985; Ichihara et al, 1988). These findings are in general
regarded as ‘loss of polar distribution’ of membrane-associated anti-
gens as a result of malignant transformation. Overproduction of CEA
and CA19-9 in cancer cells may leak into the surrounding stroma and
eventually result in an increment in their plasma levels (Hamada 
et al, 1985; Ichihara et al, 1988). EBAG9/RCAS1 has been identified
as a membrane molecule which acts as a ligand in putative receptor
present cells (Nakashima et al, 1999). Previously, Sonoda et al (1996)
detected the EBAG9/RCAS1 protein in the vaginal discharges of
EBAG9/RCAS1-positive cervical carcinoma patients. Therefore,
EBAG9 protein may be secreted from breast carcinoma cells which
in turn is likely to elevate the serum levels of EBAG9 in these
patients. To date, no studies have examined the serum levels of
EBAG9 protein in cancer patients, and the possible significance of
EBAG9 as a serum tumour marker should be validated by further
analyses in various human neoplasms including breast carcinoma. 
In this study, EBAG9 immunoreactivity was inversely associ-
ated to infiltration of mononuclear cells (P = 0.0020) and CD3+
T lymphocytes (P = 0.0025). Recently, Nakashima et al (1999)
reported that activated CD3+ T lymphocytes express a putative
receptor for EBAG9/RCAS1, and that recombinant or soluble
EBAG9/RCAS1 inhibits in vitro growth of these lymphocytes. In
addition, several studies have demonstrated that the degree of
intratumoural mononuclear cells and T lymphocytes are inversely
correlated to ER-status (An et al, 1987; Whitford et al, 1990), but
not to PR-status (An et al, 1987), in human breast carcinoma
tissues. These findings were confirmed in the present study
(inverse correlation between ERα LI and mononuclear infiltration
grade (P = 0.0012) or CD3+ cell infiltration (P = 0.0024), but
no correlation between PR LI and mononuclear infiltration grade
(P = 0.29) or infiltration of CD3+ cells (P = 0.18)). An et al (1987)
also reported that the number of other mononuclear subsets,
including B lymphocytes, NK cells and macrophages, was rela-
tively small and no significant correlations were detected with
respect to ER or PR status. Results from the present study as well as
those of previous investigations above suggest that EBAG9 secreted
from carcinoma cells inhibits intratumoural T lymphocyte infiltration
via oestrogenic actions in carcinoma cells through ER. Therefore,
EBAG9 may play an important role in endocrine– immune inter-
actions such as the immune escape of breast carcinoma cells. 
It is well recognized that human cancer tissues are infiltrated
with tumour-infiltrating lymphocytes (TIL) (Balch et al, 1990), a
phenomenon known to be a manifestation of the host immune
reaction to cancer cells (Rosenberg, 1996). TIL has been reported
to be associated with improved prognosis of some carcinomas,
including lung (DiPaola et al, 1977) and colon (Naito et al, 1998)
carcinomas. However, the biological significance of TIL remains
controversial in human breast carcinoma. For instance, prognosis
of medullary-type breast carcinomas has been reported to be asso-
ciated with the number of TIL (Moore and Foote, 1949). Black
et al (1955) reported that 9 of 11 patients had high counts of TIL
even when they had regional axillary lymph node metastases, and
survived twice as long as patients without TIL. However, several
groups have reported contradictory findings in that TIL was by no
means correlated with clinical outcome of the patients (Champion
et al, 1972) or histological grade of the tumour (An et al, 1987;
Whitford et al, 1990). In this study, no significant correlations were
detected between mononuclear infiltration grade or infiltration of
CD3+ cells and prognosis, or histological grade (data not shown),
consistent with results of the later reports. In vitro studies of mononu-
clear cells isolated from breast carcinoma tissues have demonstrated
the presence of suppressor activity capable of reducing immunologic
responses (Vose et al, 1977; Vose and Moore, 1979). Further investi-
gations are necessary to clarify whether inhibition of EBAG9 expres-
sion results in improved prognosis through the increased number of
TIL in human breast carcinoma tissues.
In summary, we have demonstrated that EBAG9 is widely
distributed in human breast carcinomas using immunohistochem-
istry and RT-PCR. Immunoreactivity for EBAG9 was significantly
associated with ERα LI, and inversely associated with mononu-
clear infiltration grade or infiltration of CD3+ T lymphocytes. Our
present data suggest that EBAG9 is produced via ERs and inhibits
the infiltration of T lymphocytes in human breast carcinomas
in the possible spectrum of endocrine–immune interactions in
patients with breast carcinoma. 
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